Pelthos Therapeutics (PTHS) reported total revenue of $15.6 million for the second quarter ended June 30, 2026, including $15.4 million in Zelsuvmi net product revenue. The company reported a net loss of $23.4 million, or $6.62 per basic and diluted common share.
Zelsuvmi net product revenue increased 45% from $10.7 million in the first quarter. The company said 11,925 Zelsuvmi units were dispensed during the quarter by 4,571 unique prescribers.
- Total revenue was $15.6 million, including $183,000 of license and collaboration revenue.
- Net product revenue for Zelsuvmi was $15.4 million, up from $10.7 million in the first quarter of 2026.
- Second-quarter net loss was $23.4 million, compared with a $25.1 million loss in the first quarter.
- Cash and cash equivalents totaled $24.2 million as of June 30, 2026.
- Zelsuvmi has generated $42.3 million in net sales across its first four quarters of commercial operations.
